Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill clarifies Medicare coverage and payment rules for home infusion therapy.
It adds pharmacy services and specific infusion-related tasks to covered services, allows nurse practitioners and physician assistants to establish and review infusion plans of care, defines certain non-pump intravenous antimicrobials as home infusion drugs, establishes transitional and reduced payment rules including a 5-hour-per-day payment benchmark through 2029 and a 50% payment when a supplier is not physically present, and prevents duplicate separate payment for specific infusion supplies on days covered under the home infusion payment.
Effective date for changes is January 1, 2026.
Technical Medicare payment clarification with limited controversy and compromise features; likely if folded into a larger health/appropriations package.
Relative to its intended legislative type, this bill is a focused substantive policy change that precisely amends statutory provisions to modify Medicare coverage and payment for home infusion therapy. It includes concrete payment rules, definitions, and effective dates but provides limited fiscal, administrative, and accountability scaffolding.
Liberal emphasizes access gains; conservatives emphasize potential cost increases
Liberal emphasizes access gains; conservatives emphasize potential cost increases
Overall supportive because the bill preserves and clarifies access to home infusion services and expands provider roles.
It secures payment for pharmacy services, recognizes non-pump IV antimicrobials, and permits NPs/PAs to manage plans, improving access for underserved patients.
Some concern exists about the 50% payment reduction when suppliers are not physically present and potential unintended impacts on small home-infusion providers.
Cautiously supportive as the bill resolves payment ambiguities and standardizes rules for Medicare home infusion.
It balances access (NP/PA roles, inclusion of pharmacy services) with cost controls (50% rule, supply bundling).
Support depends on budget impact estimates and administrative clarity to avoid creating access gaps.
Mixed-to-skeptical: the bill clarifies payments and reduces duplicate payments, which aligns with fiscal stewardship.
However, it also mandates a transitional 5-hour payment benchmark and expands covered services and provider roles, potentially increasing federal spending and regulatory reach.
Concerns center on cost, federal micromanagement, and long-term budget effects.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technical Medicare payment clarification with limited controversy and compromise features; likely if folded into a larger health/appropriations package.
The bill has not accumulated any surfaced votes yet.
Liberal emphasizes access gains; conservatives emphasize potential cost increases
Technical Medicare payment clarification with limited controversy and compromise features; likely if folded into a larger health/appropriat…
Relative to its intended legislative type, this bill is a focused substantive policy change that precisely amends statutory provisions to modify Medicare coverage and payment for home infusion therapy. It includes concr…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.